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Abstract 
A variety of genome-wide profiling techniques are available to probe complementary aspects of genome structure 
and function. Integrative analysis of heterogeneous data sources can reveal higher-level interactions that cannot 
be detected based on individual observations. A standard integration task in cancer studies is to identify altered 
genomic regions that induce changes in the expression of the associated genes based on joint analysis of 
genome-wide gene expression and copy number profiling measurements. In this review, we provide a comparison 
among various modeling procedures for integrating genome-wide profiling data of gene copy number and 
transcriptional alterations and highlight common approaches to genomic data integration. A transparent 
benchmarking procedure is introduced to quantitatively compare the cancer gene prioritization performance of the 
alternative methods. The benchmarking algorithms and data sets are available at 
http://intcomp.r-forge.r-project.org 
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INTRODUCTION 
Genome-wide profiling technologies, in particular microarrays and next generation sequencing, are used to 
characterize disease-associated changes at various levels of genome function. Identification of the key players - 
genes, chromosomal regions, or biological processes - is a fundamental step towards mechanistic characterization 
of the disease and revealing molecular targets for potential therapeutic intervention. Genomic, transcriptomic, 
epigenomic, and proteomic measurements characterize different aspects of genome regulation and function that are 
particularly relevant for cancer research [1-2]. Integrative analysis has been used to prioritize disease genes or 
chromosomal regions for experimental testing, to discover disease subtypes [3-4], or to predict patient survival or 
other clinical variables [5]. Co-occurring genomic observations are increasingly available in private and public 
repositories, such as the Cancer Genome Atlas database [6] and the Leukemia Gene Atlas [7], which promotes 
wide access to data resources. However, the lack of algorithmic implementations still represents a bottleneck 
hampering integrative approaches. 
The integration of gene expression (GE) and copy number (CN) data to identify DNA copy number alterations that 
induce changes in the expression levels of the associated genes is a common task in cancer studies [8], and the 
detection of chromosomal regions with exceptionally high statistical association between CN and GE can pinpoint 
disease genes and potential cancer mechanisms [9-10]. First high-throughput analyses were reported about a decade 
ago [11-13], evidencing a clear cis-dosage effect of CN alterations on GE levels [14-16]. Although the downstream 
effect of CN alteration on gene expression is still a focus of ongoing research [17-18], a systematic quantitative 
comparison of alternative approaches for integrating GE/CN data sets has been missing, as clearly highlighted by 
the recent review by Huang et al [8]. Hence, we designed a transparent and quantitative benchmarking procedure to 
compare publicly available methods for cancer gene prioritization from the integrative analysis of CN/GE profiling 
data. This benchmark approach was applied to assess and compare the performance of 12 algorithms on two 
simulated data sets and three real case studies. In the following sections, we overview available methodologies for 
cancer gene prioritization based on GE/CN data integration, introduce the analysis pipeline, and discuss 
benchmarking results. 
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Quantifying associations between gene expression and copy number 
Two-step approaches Several approaches separately assess the alterations in each data set and compare results 
from CN and GE analyses to detect simultaneous changes, mostly modeling changes in GE based on the CN 
signals [16,19]. This corresponds to the biological intuition concerning the cis-regulatory effect of CN alterations. 
In the first step samples are grouped based on hard CN calls, call probabilities [20] or quantiles (DR-SAM [21]). In 
the second step, differential gene expression is quantified between such groups using e.g., standard approaches for 
GE data analysis as t-test [13], nonparametric alternatives [22] or permutation tests [23-24]. Some methods focus 
on regions rather than probes/genes [19, 24]. Comparison of gene expression levels between the sample groups 
with distinct copy number status on a particular chromosomal region is aimed to reveal copy number-induced 
transcriptional responses, typically within the affected region. 
Regression approaches Another class of tools uses regression models with CN as the predictor and GE as the 
response variable, again following biological intuition concerning the cis-regulatory effect of CN alterations. Both 
linear [12] and non-linear regression models [25] have been proposed. Regression models have been designed both 
based on one-to-one correspondence between CN and GE probes [26] and multiple/multivariate linear regression 
[14, 26-28]. 
Correlation-based approaches The DR-Correlate [21] and a modified version of Ortiz-Estevez algorithm [16] use 
correlation-based analysis to scan over the genome to detect loci with exceptionally high associations between 
CN/GE. Schäfer et al. [29] substitute the sample means by the reference medians, and Lipson et al. [30] use 
quantile-based analysis to obtain improved correlation coefficients. Canonical correlation analysis (CCA) identifies 
linear combinations of CN and GE probes that are maximally correlated. Various modifications for dimensionality 
reduction and model regularization have been proposed based on principal component analysis [31] and penalized 
approaches based, e.g., on LASSO or elastic net to obtain sparse versions of CCA [5, 32-33], or based on variants 
that focus on specific types of dependency [34].  Regularization can reduce overfitting, and sparsity can simplify 
interpretation of the results, but determining appropriate regularization parameters may represent a challenging 
issue. 
Latent variable models Latent variable approaches model directly the data-generating processes and noise. The 
pint/simcca [34] decomposes GE and CN data sets into shared and independent Gaussian components based on 
regularized probabilistic CCA. The algorithm by [4] is a related model suited for sample classification and subtype 
discovery. Latent matrix decomposition models and iterative, dependency-seeking projections have also been 
suggested based on generalized singular-value decomposition [3] and independent component analysis [35]. 
Benchmarking the algorithms 
Manual literature search in PubMed and Google Scholar using combinations of the keywords ‘gene expression’, 
‘copy number’, ‘integration’, and curation of the Bioconductor repository (http://www.bioconductor.org) were 
performed to identify available implementations, yielding 12 algorithms that were applicable for cancer gene 
prioritization based on integrative analysis of GE/CN data (Table 1). The source code for Ortiz-Estevez [16] was 
obtained from the authors. An automated benchmarking pipeline (‘intcomp’) was created to compare method 
performance on two simulated data sets and three real case studies. Calculations were carried out in R (2.13.2 [36] 
and intcomp v. 0.3.27). The comparison pipeline is available through R-Forge 
(http://intcomp.r-forge.r-project.org/) and the algorithm versions are detailed in the package vignette. 
Each method was used to prioritize candidate cancer genes, followed by comparison to a golden standard list of 
known cancer genes, and ranking of the methods based on (i) true positive rate among the top findings, (ii) receiver 
operating characteristic (ROC) analysis of the overall prioritized gene list, and (iii) running times. Since only a 
subset of genes are likely to be cancer-associated, the standard Area Under Curve (AUC) analysis, which considers 
the overall prioritized gene list, was complemented by investigating the true positive rate among the top findings. 
This is more appropriate in particular for methods such as CNAmet, Ortiz-Estevez, or PREDA/SODEGIR, which 
have originally been designed to detect altered chromosomal regions rather than to prioritize individual genes. 
Default parameters for each method were used where possible. The following exceptions were made to apply the 
algorithms to cancer gene prioritization. In DR-Correlate [21], empirical p-values from 1000 random gene 
permutations were used to rank the genes. The DR-Correlate t-test option was not applicable on the Ferrari 
simulations due to the low number of replicate samples. CNAmet [24, 37] requires called CN values and provides 
separate lists for amplifications and deletions; thus, the two lists were pooled and ranked based on the p-values. 
Moreover, to enable an unbiased AUC comparison of CNAmet with all other methods (that prioritize all genes), 
random ranks were assigned to genes labeled by CNAmet with no p-value (non-significant genes). With 
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intCNGEan [20], the weighted Mann-Whitney test with univariate analysis was used with an effective p-value 
threshold of 0.1. In pint/simcca [34], segmented CN data was used only when the resolution of the CN platform 
was higher than the resolution of the GE microarray. In PREDA/SODEGIR we used ‘spline’ for smoothing, 1000 
random gene orderings of the output regions, and the median AUC as an unbiased output for gene prioritization.  
For all methods, each CN probe/segment has been matched to the closest/corresponding GE probe within the same 
chromosomal arm [34, 38], although the preprocessing of CN data depends partially on the platform resolution [8]. 
On the latest high-density SNP arrays, for instance, segmentation strategies are essential for estimating the CN for 
individual genes [8]. Various approaches consider to investigate only certain genomic regions at a time, e.g. to 
avoid bias, and propose different strategies to select the size of the chromosomal region, including fixed windows 
in terms of consecutive probes or base pairs [28, 30, 34], chromosome arms or minimal common regions [26] or 
performing kernel regression [19] where the probe signals are modeled with a smoothing function which accounts 
for the non-uniform distribution of the genes along the genome.  
Simulated data Two simulated data sets were generated following Schäfer et al. ([29]; 'Schäfer' data set) and 
Bicciato et al. ([19]; 'Ferrari' data set). For the 'Schäfer' data set, CN and GE values are drawn from a normal 
mixture where two components represent aberrations of different extent for each locus; 100 samples were created 
for each input with mixture proportions of either 10% or 90% for the affected and normal regions. Varying noise 
levels were imposed using multiple variance parameters (0.25, 0.5, 1, 2 and 4 times an adjusted median absolute 
deviation of the data). The data points are organized in 16 equally sized blocks to mimic affected regions. The 
'Ferrari' data with 6 samples was created by manipulating a renal cell carcinoma data set through permutation of 
loci and adding or subtracting constants to both CN and GE values within 10 blocks of 10 Mbp. Normal control 
data was generated by subtracting the median across the samples [19]. 
Real case studies Benchmarking on real case studies is crucial, but defining the ground truth is more challenging 
than in simulation studies. We investigated two breast cancer data sets [12-13] and a leukemia study [39] using 
expert-curated lists of known breast cancer genes [40], and leukemia genes from the Cancer Gene Census [41] as 
the ground truth for the comparisons, respectively. The ‘Hyman’ data set [13] contains 14 breast cancer cell lines, 
preprocessed as in [3]. The 'Pollack' data set [12] contains 41 breast cancer samples. The 'Mullighan' data set 
consists of 171 acute lymphoblastic leukemia (ALL) samples divided in 9 subtypes [39, 42]. CN data (Affymetrix 
Human Mapping 500K) was downloaded from ftp://ftp.stjude.org and normalized with CRMA v2 [43]. The 
log-additive model from the CRMA v1 algorithm [44] was used for probe summarization. Data values from Nsp 
and Sty array of the 500K array set were combined and segmented with CBS [45]. Gene expression profiles of the 
same ALL specimens, measured with the Affymetrix HG-U133A platform were obtained from GEO (GSE12995; 
[46] and preprocessed with the RPA algorithm (R/Bioconductor; [47]) and EntrezID-based custom chip definition 
file (v13; [48]). The reference for GE and CN data was defined as the median normalized log-ratios across all 
samples. Probes with no EntrezID or location information and probes mapping to multiple locations or in sex 
chromosomes were excluded. GE and CN probes were matched by selecting for each gene the closest CN probe. 
Missing values were imputed by Gaussian random samples using the mean and variance of the data. 
 
Implementation CN preprocessing Methodological character Significance scoring  Reference 
CNAmet (R) called custom statistic; two-step PPT; aberrant regions Hautaniemi et al., 2004; 
    
Louhimo and Hautaniemi 2011 
DR-Correlate / t-test (BC) raw/segmented  two-step PPT; p-values Salari et al. 2010 
DR-Correlate (BC) raw/segmented  COR PPT; p-values Salari et al. 2010 
/ Pearson, Spearman  
    edira (R) raw/segmented  custom statistic; COR NT; p-values Schäfer et al. 2009 
intCNGEan (R) cghCall object custom statistic; two-step PNT; p-values van Wieringen et al. 2009 
Ortiz-Rivas (R) raw/segmented  two-step PNT; p-values Ortiz et al. 2011 
PMA (CRAN) raw/segmented  LV; COR PLV; p-values Witten et al. 2009 
PREDA (BC)  raw/segmented  custom statistic; two-step PPT; aberrant regions/ Bicciato et al. 2009;  
   
q-values Ferrari et al., 2011 
pint/simcca (BC) raw/segmented  LV; COR PLV; custom statistic Lahti et al. 2009 
SIM (BC) raw/segmented  REG PT; p-values Menezes et al. 2009 
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Table 1 Summary of the comparison algorithms. The implementations are available through Bioconductor (BC); 
CRAN; or R source code (R). The copy number preprocessing methods required by each algorithm are listed. 
Abbreviations: Correlation analysis (COR), regression analysis (REG), latent variables analysis (LV), parametric 
test (PT), nonparametric test (NT), permutation test based on statistic of nonparametric test (PNT), permutation test 
based on statistic of parametric test (PPT), permutation test based on latent variable score (PLV). 
Results 
The overall cancer gene prioritization performance for the complete gene lists quantified by the AUC analysis is 
summarized in Figure 1 (for the ROC curves, see Supplementary Figure S1). The highest median ranking across 
the five benchmarking data sets was obtained by edira (1), followed by Ortiz-Estevez (4) and pint/simcca (4). of 
these three methods outperformed the other methods on at least one data set. Note that the performance of edira 
regarding the 'Schäfer' data set and of PREDA/SODEGIR regarding the 'Ferrari' data set needs to be interpreted 
carefully, because these simulations were originally constructed to follow the particular modeling assumptions of 
these algorithms in the original publications [19, 29].  
Considering the true positive rate among the top-200 genes of each algorithm, pint/simcca had the highest median 
ranking (1), followed by edira, Ortiz-Estevez and PREDA/SODEGIR (3; Figure 2). These four methods had 
systematically the highest median rankings with multiple thresholds (20, 50, and 100 top genes); Notably, although 
edira and PREDA/SODEGIR had the highest scores in the AUC analysis on the Schäfer data, most of other 
algorithms outperformed these methods with respect to known true positives among the top findings in this data 
set. 
Differences regarding the running times were considerable (Supplementary Table 1). Evaluations were performed 
on a 64-bit Linux machine with 2 AMD Opteron 2382 processors (K10 architecture, 4 kernels per processor, 2.6 
GHz, 32 GB RAM); edira and PMA were the fastest methods with less than one minute running time in all data 
sets, closely followed by Ortiz-Estevez with a maximum running time of less than 3 minutes. The number of 
permutations in significance testing affects remarkably the running times of CNAmet, DR-Correlate, intCNGEan 
and PREDA, although in the latest version of PREDA a parallelized version of the algorithm has been implemented 
to reduce the computation time [49]. 
 
Figure 1 Area under curve (AUC) values in ROC analysis quantify cancer gene prioritization performance of the 
methods for the 5 benchmarking data sets. High values indicate high true positive vs. false positive ratio among the 
top findings; the dashed line indicates the expected AUC value for a random gene list (AUC = 0.5). The methods 
have been ordered by their median rank across all data sets. For the ROC curves, see Supplementary Figure S1. 
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Figure 2 True positive rates among the top-200 genes from each comparison algorithm across the 5 benchmarking 
data sets. The overall true positive rate is low in real case studies and the scale for the ‘Hyman’, ‘Mullighan’ and 
‘Pollack’ data sets has been accordingly adjusted to highlight the differences. The methods have been ordered as in 
Figure 1. 
Discussion 
Prioritization of disease genes is a key-modeling task in functional genomics [50-53]. This review provides an 
overview and quantitative benchmarking of publicly available algorithms for detecting associations between GE 
and CN alterations. This complements the recent review by Huang et al., [8], who pointed out the lack of 
quantitative comparisons of the available methods. The ‘intcomp’ benchmarking package applied in this review is 
freely available at R-forge (http://intcomp.r-forge.r-project.org/), facilitating transparent comparisons and the 
addition of new algorithms, benchmarking procedures, and validation data sets. 
The comparison of 12 different algorithms with respect to their performance in cancer gene prioritization revealed 
systematic differences between the methods across different data sets, preprocessing scenarios, and sample sizes. 
The model performance is in general better in the simulation studies, compared to the real cancer data sets, 
suggesting that manually curated cancer gene lists may be only rough approximations of the ground truth in the real 
case studies and that the simulations may have lower noise levels. Simulation procedures are only rough 
approximations of the biological reality and the simulation approach can remarkably affect model performance. For 
instance, variants of DR-Correlate and CNAmet performed well with ‘Schäfer’ simulated data but their 
performance dropped close to random expectation in the ‘Ferrari’ data set. The ‘Ferrari’ simulations assume that 
the CN effect is visible in all tumor samples, which can be particularly disadvantageous for methods that assume 
high variation from heterogeneous aberration profiles across the samples, including DR-Correlate. The ‘Ferrari’ 
and ‘Schäfer’ simulated data sets were originally introduced in the PREDA/SODEGIR and edira publications 
which potentially causes positive bias on these methods in the respective data sets. Overall, edira, Ortiz-Estevez, 
and pint/simcca consistently outperformed the other methods. Considering both relative performance and running 
time, edira and Ortiz-Estevez seem to offer a good trade-off but all methods have acceptable running times for 
practical applications. 
The choice of preprocessing and model parameters can have a remarkable effect on the results. The key decisions 
in the context of GE/CN data are associated with selecting the CN preprocessing approach [54], size of the 
investigated regions, and the matching approach for the integrated data sets. These and related issues are 
extensively discussed in the recent review by Huang et al. [8]. It is also possible to utilize class information of the 
samples, for instance by including both tumor and reference samples as in the DR-SAM algorithm [21]. However, 
in many cases the references are included as a pooled control for two-color microarray experiments but not as a 
separate group, as with the Hyman and Pollack data sets. Moreover, genomic aberrations often affect only a subset 
of the cancer patients, and multiple cancer subtypes may be present, as for instance in the Mullighan data set. 
Further integrative tasks include modeling of trans-regulatory effects of CN aberrations on genes outside the 
affected region [55-56], disease subtype discovery [4], prediction of patient survival or of clinical covariates [57] 
and integrative analysis of other data sources such as methylation [58], micro-RNA [59-60], or protein expression 
[61]. However, fewer implementations for such tasks are currently available. Availability of reference 
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implementations for new computational approaches would facilitate benchmarking and optimizing the algorithms. 
The standardized benchmarking pipeline introduced in this review can be adjusted to incorporate additional 
algorithms and data sets as they become available. 
CONCLUSION 
A variety of methods is available for the integrative analysis of gene expression and copy number data. The 
algorithms can be classified as two-step, regression, correlation-based, and latent variable approaches. 
Implementation quality, running time and accuracy of the algorithm, as well as preprocessing, sample size and 
availability of control samples need to be considered when selecting the appropriate computational method. The 
benchmarking pipeline reveals systematic differences in cancer gene prioritization performance of available 
implementations across five case studies. 
KEY POINTS 
– The integrative analysis algorithms for gene expression and copy number data include two-step, regression, 
correlation-based, and latent variable approaches 
– The benchmarking pipeline reveals systematic differences in the cancer gene prioritization performance of 
currently available implementations 
– Implementation quality, running time and accuracy of the algorithm, as well as data preprocessing,  
sample size and availability of control samples need to be considered when selecting the analysis approach 
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Supplementary Material 
 
Ferrari Schaefer Hyman Mullighan Pollack 
CNAmet  106.96 52.34 77.44 28.38 44.99 
DR-Cor/Pearson  168.50 61.11 70.26 24.39 41.41 
DR-Cor/Spearman  310.52 120.40 135.04 45.08 78.41 
DR-Cor/t-test  - 67.52 68.02 26.18 43.38 
edira  0.41 0.23 0.22 0.11 0.15 
intCNGEan  5.74 47.64 20.05 45.64 23.95 
Ortiz-Estevez  0.53 2.84 0.65 1.24 1.07 
pint    86.20 130.20 29.75 6.80 19.13 
PMA 0.34 0.33 0.18 0.17 0.13 
PREDA  79.23 155.65 59.95 360.60 106.53 
SIM/full  87.51 155.96 13.63 4.77 5.14 
SIM/window  19.15 171.96 2.81 1.28 1.40 
 
Supplementary Table 1 Running times (in minutes) for the comparison algorithms in the five benchmarking data 
sets. 
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Supplementary Figure 1 Receiver-Operator Characteristic (ROC) curves characterize the cancer gene 
prioritization performance of the comparison algorithms in two simulated data sets (‘Ferrari’ and ‘Schäfer’), two 
breast cancer data sets (‘Hyman’ and ‘Pollack’), and one leukemia data set (‘Mullighan’) based on golden standard 
lists of custom cancer genes. 
